A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours

British Journal of Cancer

Volumn 111, Issue 10, 2014, Pages 1932-1944

  Brana, I ^a   Berger, R ^b   Golan, T ^b   Haluska, P ^c   Edenfield, J ^d   Fiorica, J ^e   Stephenson, J ^d   Martin, L P ^f   Westin, S ^g   Hanjani, P ^h   Jones, M B ⁱ   Almhanna, K ^j   Wenham, R M ^j   Sullivan, D M ^j,k   Dalton, W S ^k   Gunchenko, A ⁱ   Cheng, J D ⁱ   Siu, L L ^a   Gray, J E ^j  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b SHEBA MEDICAL CENTER   (Israel)

^c MAYO CLINIC   (United States)

^d GREENVILLE HOSPITAL SYSTEM   (United States)

^e SARASOTA MEMORIAL HOSPITAL   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g UNIVERSITY OF TEXAS   (United States)

^h ABINGTON MEMORIAL HOSPITAL   (United States)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

^j H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^k M2Gen   (United States)

more..

Author keywords

colorectal cancer; dalotuzumab; MK 0752; MK 2206; ovarian cancer; ridaforolimus

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; DALOTUZUMAB; GAMMA GLUTAMYLTRANSFERASE; MK 0752; RIDAFOROLIMUS; SOMATOMEDIN C; 3-(4-((4-CHLOROPHENYL)SULFONYL)-4-(2,5-DIFLUOROPHENYL)CYCLOHEXYL)PROPANOIC ACID; ANTINEOPLASTIC AGENT; BENZENE DERIVATIVE; FUSED HETEROCYCLIC RINGS; MONOCLONAL ANTIBODY; MTOR PROTEIN, HUMAN; NOTCH RECEPTOR; PROPIONIC ACID DERIVATIVE; PROTEIN KINASE B; RAPAMYCIN; SOMATOMEDIN C RECEPTOR; SULFONE; TARGET OF RAPAMYCIN KINASE; TUMOR MARKER;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CARCINOMA; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM INFLAMMATION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; DRY SKIN; DYSGEUSIA; ENDOMETRIUM SARCOMA; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE EXPRESSION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFUSION RELATED REACTION; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LEUKOPENIA; LIMB PAIN; MACULOPAPULAR RASH; MALE; MELANOMA; MOUTH PAIN; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVARY CANCER; OVARY CARCINOMA; PANCREAS CARCINOMA; PARALLEL DESIGN; PERIPHERAL EDEMA; PERITONEUM CANCER; PETECHIA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOLID TUMOR; STOMATITIS; SYSTEMIC THERAPY; T WAVE INVERSION; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; UTERINE TUBE TUMOR; XEROSTOMIA; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CLINICAL TRIAL; COHORT ANALYSIS; FOLLOW UP; METABOLISM; MIDDLE AGED; NEOPLASMS; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TISSUE DISTRIBUTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENE DERIVATIVES; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PROGNOSIS; PROPIONATES; PROTO-ONCOGENE PROTEINS C-AKT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, IGF TYPE 1; RECEPTORS, NOTCH; SIROLIMUS; SULFONES; TISSUE DISTRIBUTION; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84922480694     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.497     Document Type: Article

References (56)

1. Aster JC, Blacklow SC (2012) Targeting the Notch pathway: twists and turns on the road to rational therapeutics. J Clin Oncol 30: 2418-2420
2. Atzori F, Tabernero J, Cervantes A, Prudkin L, Andreu J, Rodriguez-Braun E, Domingo A, Guijarro J, Gamez C, Rodon J, Di Cosimo S, Brown H, Clark J, Hardwick JS, Beckman RA, Hanley WD, Hsu K, Calvo E, Rosello S, Langdon RB, Baselga J (2011) A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 17: 6304-6312
3. Avnet S, Sciacca L, Salerno M, Gancitano G, Cassarino MF, Longhi A, Zakikhani M, Carboni JM, Gottardis M, Giunti A, Pollak M, Vigneri R, Baldini N (2009) Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res 69: 2443-2452
4. Baserga R, Peruzzi F, Reiss K (2003) The IGF-1 receptor in cancer biology. Int J Cancer 107: 873-877
5. Becerra C, Salazar R, Garcia-Carbonero R, Thomas AL, Vazquez-Mazon F, Cassidy J, Maughan T, Gallen M, Iveson T, Hixon M, Gualberto A, Yin D, Bergsland EK, Li D (2011) Phase II trial of figitumumab in patients with refractory, metastatic colorectal cancer (mCRC). 2011 ASCO Annual Meeting; 9 June 2011; Chicago, IL, USA, Abstract 3525
6. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson Jr JA, Marks JR, Dressman HK, West M, Nevins JR (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357
7. Biondo A, Yap TA, Yan L, Patnaik A, Fearen I, Baird RD, Papadopoulos KP, Delgado LM, Taylor A, Lupinacci L, Blackman SC, Decordova S, Tall M, Heaton S, Garrett MD, Sullivan D, De Bono JS, Tolcher AW (2011) Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors. 2011 ASCO Annual Meeting; 20 May 2011; Chicago, IL, USA, Abstract 3037
8. Blum R, Elkon R, Yaari S, Zundelevich A, Jacob-Hirsch J, Rechavi G, Shamir R, Kloog Y (2007) Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid). Cancer Res 67: 3320-3328
9. Broussas M, Dupont J, Gonzalez A, Blaecke A, Fournier M, Corvaia N, Goetsch L (2009) Molecular mechanisms involved in activity of h7C10, a humanized monoclonal antibody, to IGF-1 receptor. Int J Cancer 124: 2281-2293
10. Calvo E, Ma W, Tolcher AW, Hidalgo M, Soria J, Bahleda R, Gualberto A, Denis LJ, Millham RD, Adjei AA (2010) Phase (P) I study of PF-00299804 combined with figitumumab (FI; CP-751, 871) in patients (pts) with advanced solid tumors (ASTs). 2010 ASCO Annual Meeting; 14 June 2010; Chicago, IL, USA, Abstract 3026
11. Cao ZA, Pinzon-Ortiz M, Chen Y, Li X, Beltran PJ, Gansert JL, Peters M, Schlegel R, Schumacher KM, Huang A (2013) Targeting PIK3CA mutant breast cancer with the combination of PIK3CA-specific inhibitor, BYL719, and IGF1-R antibody, ganitumab. 2013 ASCO Annual Meeting; 17 June 2013; Chicago, IL, USA, Abstract e13525
12. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-566
13. Daidone MG, Foekens JA, Harbeck N, Martens J, Brunner N, Thomssen C, Hall JA, Salgado R, Dittmer J, Geurts-Moespot A, Duffy MJ, Sweep FCGJ, Schmitt M (2012) Identification, validation and clinical implementation of cancer biomarkers: translational strategies of the EORTC PathoBiology Group. Eur J Cancer 10: 120-127
14. Dancey JE, Dobbin KK, Groshen S, Jessup JM, Hruszkewycz AH, Koehler M, Parchment R, Ratain MJ, Shankar LK, Stadler WM, True LD, Gravell A, Grever MR (2010) Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res 16: 1745-1755
15. Di Cosimo S, Bendell JC, Cervantes-Ruiperez A, Roda D, Prudkin L, Stein MN, Leighton-Swayze A, Song Y, Ebbinghaus S, Baselga J (2010) A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors. 2010 ASCO Annual Meeting; 14 June 2010, Chicago, IL, USA, Abstract 3008
16. Di Cosimo S, Seoane J, Guzman M, Rojo F, Jimenez J, Anido J, Arribas J, Cognetti F, Baselga J (2005) Combination of the mammalian target of rapamycin (mTOR) inhibitor everolimus (E) with the insulin like growth factor-1-receptor (IGF-1-R) inhibitor NVP-AEW-541: a mechanistic based anti-tumor strategy. 2005 ASCO Annual Meeting; 28 May 2005, Orlando, FL, USA, Abstract 3112
17. Ebbinghaus S, Blum JL, Cortes J, Rugo HS, Swanton C, Eaton L, Song Y, Zhang T, Baselga J (2011) A phase II study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor-positive (ER') breast cancer. 2011 ASCO Meeting; 9 June 2011, Chicago, IL, USA, Abstract: TPS110
18. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247
19. Eliasz S, Liang S, Chen Y, De Marco MA, Machek O, Skucha S, Miele L, Bocchetta M (2010) Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. Oncogene 29: 2488-2498
20. Gao J, Chang YS, Jallal B, Viner J (2012) Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology. Cancer Res 72: 3-12
21. Guha M (2013) Anticancer IGF1R classes take more knocks. Nat Rev Drug Discov 12: 250-250
22. Gusscott S, Kuchenbauer F, Humphries RK, Weng AP (2012) Notch-mediated repression of miR-223 contributes to IGF1R regulation in T-ALL. Leuk Res 36: 905-911
23. Hägerstrand D, Lindh MB, Peña C, Garcia-Echeverria C, Nistér M, Hofmann F, Östman A (2010) PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541. Neuro-Oncology 12: 967-975
24. Haines BB, Wick MJ, Papadopoulos KP, Tolcher AW, Tammam JG, Chaney MF, Nebozhyn M, Zhang T, Ebbinghaus SW, Cheng JD, Zawel L, Sathyanarayanan S (2012) Response biomarkers to IGF1R and mTOR inhibitor combination therapy in ovarian carcinoma. AACR 103rd Annual Meeting; 31 March-4April, Chicago, IL, USA, Abstract 1868
25. Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, Paccagnella ML, De Bono JS, Gualberto A, Hammer GD (2010) Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 65: 765-773
26. Jassem J, Langer CJ, Karp DD, Mok T, Benner RJ, Green SJ, Park K, Novello S, Strausz J, Gualberto A (2010) Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). 2010 ASCO Annual Meeting; 14 June 2010, Chicago, IL, USA, Abstract 7500
27. Ji Y, Liu P, Li Y, Bekele BN (2010) A modified toxicity probability interval method for dose-finding trials. Clin Trials 7: 653-663
28. Ji Y, Wang SJ (2013) Modified toxicity probability interval design: a safer and more reliable method than the 3'3 design for practical phase I trials. J Clin Oncol 31: 1785-1791
29. Krop I, Demuth T, Guthrie T, Wen PY, MasonWP, Chinnaiyan P, Butowski N, Groves MD, Kesari S, Freedman SJ, Blackman S, Watters J, Loboda A, Podtelezhnikov A, Lunceford J, Chen C, Giannotti M, Hing J, Beckman R, LoRusso P (2012) Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol 30: 2307-2313
30. Loboda A, Nebozhyn M, Klinghoffer R, Frazier J, Chastain M, Arthur W, Roberts B, Zhang T, Chenard M, Haines B, Andersen J, Nagashima K, Paweletz C, Lynch B, Feldman I, Dai H, Huang P, Watters J (2010) A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. BMC Med Genomics 3: 26
31. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ (1999) Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91: 620-625
32. Macaulay VM, Middleton MR, Protheroe AS, Tolcher A, Dieras V, Sessa C, Bahleda R, Blay JY, LoRusso P, Mery-Mignard D, Soria JC (2013) Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors. Ann Oncol 24: 784-791
33. Manji A, Brana I, Amir E, Tomlinson G, Tannock IF, Bedard PL, Oza A, Siu LL, Abdul Razak AR (2013) Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials. J Clin Oncol 31: 4260-4267
34. Medyouf H, Gusscott S, Wang H, Tseng JC, Wai C, Nemirovsky O, Trumpp A, Pflumio F, Carboni J, Gottardis M, Pollak M, Kung AL, Aster JC, Holzenberger M, Weng AP (2011) High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. J Exp Med 208: 1809-1822
35. Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly GJ, Goldston M, Patnaik A, Mathews L, Ricart AD, Mays T, Knowles H, Rivera VM, Kreisberg J, Bedrosian CL, Tolcher AW (2008) Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 26: 361-367
36. Mita MM, Poplin E, Britten CD, TapWD, Rubin EH, Scott BB, Berk L, Rivera VM, Loewy JW, Dodion P, Haluska F, Sarantopoulos J, Mita A, Tolcher A (2013) Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma. Ann Oncol 24: 1104-1111
37. Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, Hong D, Chen HX, Doyle LA, Heilbrun LK, Rohren E, Ng C, Chandhasin C, LoRusso P (2011) Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res 17: 6052-6060
38. Naumov G, Howard S, Seeley A, Ware C, Reilly J, Cheng J, Sathyanarayanan S (2012) Development of novel combination therapy with dalotuzumab and GSI for the treatment of cetuximab refractory colorectal cancer. 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; November, Dublin, Ireland, Abstract 299
39. O'Reilly KE, Rojo F, She Q-B, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508
40. Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Paccagnella ML, Batzel GN, Yin D, Pritchard-Jones K, Judson I, Worden FP, Gualberto A, Scurr M, De Bono JS, Haluska P (2010) Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751, 871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 11: 129-135
41. Pandini G, Wurch T, Akla B, Corvaia N, Belfiore A, Goetsch L (2007) Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur J Cancer 43: 1318-1327
42. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928
43. Pollak M (2012) The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clin Cancer Res 18: 40-50
44. Quek R, Wang Q, Morgan JA, Shapiro GI, Butrynski JE, Ramaiya N, Huftalen T, Jederlinic N, Manola J, Wagner AJ, Demetri GD, George S (2011) Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res 17: 871-879
45. Ranganathan P, Weaver KL, Capobianco AJ (2011) Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer 11: 338-351
46. Ray-Coquard I, Haluska P, O'Reilly S, Cottu PH, Elit L, Provencher DM, Beckmann MW, Bosserman LD, Jacod S, Houe V, Loberg RD, Glaspy JA, Karlan B, Slamon DJ, Konecny GE (2013) A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinumsensitive ovarian cancer. 2013 ASCO Annual Meeting; 17 June 2013; Chicago, IL, USA, Abstract 5515
47. Rowlands M-A, Gunnell D, Harris R, Vatten LJ, Holly JMP, Martin RM (2009) Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 124: 2416-2429
48. Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Sagae S, Greven K, Parmar M, Friedlander M, Cervantes A, Vermorken J (2011) Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 21: 419-423
49. Schmitz S, Kaminsky-Forrett MC, Henry S, Zanetta S, Geoffrois L, Bompas E, Moxhon A, Mignion L, Guigay J, Knoops L, Hamoir M, Machiels JP (2012) Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02). Ann Oncol 23: 2153-2161
50. Sweet-Cordero A, Mukherjee S, Subramanian A, You H, Roix JJ, Ladd-Acosta C, Mesirov J, Golub TR, Jacks T (2005) An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet 37: 48-55
51. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, SRy Cajal, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebwohl D, Baselga J (2008) Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26: 1603-1610
52. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ (2006) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26: 1932-1940
53. Watkins DJ, Ayers M, Cunningham D, Tabernero J, Tejpar S, Kim TY, Kim TW, Kim SY, Roh JK, Beale PJ, Park YS, Guren TK, Loboda A, Nebozhyn M, Mogg R, Lunceford J, Schmidt EV, Brown HM, Sathyanarayanan S, Mauro DJ (2012) Molecular analysis of the randomized phase II/III study of the anti-IGF-1R antibody dalotuzumab (MK-0646) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory KRAS wild-type metastatic colorectal cancer (mCRC). 2012 ASCO Annual Meeting; 20 May 2012; Chicago, IL, USA, Abstract 3531
54. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, Riisnaes R, Pope LL, Heaton SP, Thomas G, Garrett MD, Sullivan DM, De Bono JS, Tolcher AW (2011) First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29: 4688-4695
55. Yee D (2012) Insulin-like growth factor receptor inhibitors: baby or the bathwater?. J Natl Cancer Inst 104: 975-981
56. Zhang CC, Yan Z, Zong Q, Fang DD, Painter C, Zhang Q, Chen E, Lira ME, John-Baptiste A, Christensen JG (2013) Synergistic effect of the gammasecretase inhibitor PF-03084014 and docetaxel in breast cancer models. Stem Cells Transl Med 2: 233-242